Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 576-skin-graft-except-for-skin-ulcer-or-cellulitis-with-mcc
    Ask Trek AI about this page

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    DRG 576 encompasses inpatient admissions for skin graft procedures (excluding those for skin ulcers or cellulitis) accompanied by a Major Complication or Comorbidity; it denotes higher clinical complexity. This designation matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity raises the relative weight and associated Medicare payment to reflect greater resource utilization.

    Customize your policy alerts

    Sign up for drg 576 policy alerts

    Get alerted when payer policies referencing 576 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 576 Overview

    DRG 576 covers hospital admissions for skin graft procedures not performed for treatment of skin ulcers or cellulitis and that include a Major Complication or Comorbidity. Typical cases include extensive burn coverage, traumatic skin loss, or large reconstructive grafting where significant acute physiologic disturbances or severe comorbid conditions are present. This Diagnosis-Related Group has higher relative payment weight because the presence of a Major Complication or Comorbidity increases expected resource use, length of stay, and intensity of inpatient services under Centers for Medicare & Medicaid Services payment policy.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute surgical technique and perioperative optimization trials: randomized or prospective cohort studies comparing different skin graft harvesting and fixation methods, adjunctive intraoperative technologies (such as negative-pressure wound therapy applied immediately over grafts), and enhanced perioperative protocols (analgesia, hemostasis, and infection prophylaxis). These studies enroll adult inpatients undergoing split-thickness or full-thickness skin grafts for traumatic wounds, burns, or reconstructive defects excluding primary ulcers or cellulitis, with a focus on graft take rates, early complications (hematoma, seroma, infection), and length of stay. Results are directly relevant to surgeons and hospital revenue managers because improvements in graft survival and reduced complications can shorten LOS and ICU needs, lower readmission risk, and influence resource utilization and DRG case-mix costs.
    • Comparative effectiveness and cost-effectiveness studies of biologic and dressing adjuncts to grafting: observational cohorts and pragmatic randomized trials evaluating topical biologic matrices, cellular skin substitutes, advanced dressings, or antibiotics-impregnated materials used as adjuncts to standard grafting in complex wounds without primary ulceration or cellulitis. These trials typically enroll medically complex inpatients (eg, patients with peripheral vascular disease, diabetes mellitus, immunosuppression, or large surface-area defects) to compare outcomes such as time to definitive wound closure, need for re-grafting, secondary infection rates, and total inpatient episode costs. Payers and hospital administrators rely on this evidence to decide reimbursement policies and formulary placement for expensive adjuncts and to predict downstream costs associated with failed grafts or prolonged hospitalization under DRG 576.
    • Post-discharge outcomes and rehabilitation research: prospective registry studies and longitudinal outcomes research tracking functional recovery, wound-related readmissions, outpatient dressing change needs, and quality-of-life after inpatient skin grafting for non-ulcer/cellulitis indications. These studies follow diverse discharge populations—including elderly patients, those with limited social support, and patients requiring home health or skilled nursing facility care—to identify predictors of readmission, durable wound closure, and long-term resource use. Findings inform discharge planning protocols, transitional care interventions, and payer strategies to reduce preventable readmissions and optimize post-acute spending tied to episodes bundled under this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.